Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia (BBD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Charles, Missouri, United States, 63301
- Lindenwood University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All participants will be between the ages of 18-45 years.
- Participants will be healthy and free of disease as determined by evaluation of a medical history
- Body mass index (BMI) between 18.5 - 30 kg/m^2
Exclusion Criteria:
- Those individuals less than 18 and greater than 45 years of age will be excluded.
- Participants younger than 18 are excluded due to necessity of parental consent.
- Participants greater than 45 years old lie outside of the target demographic for the current study.
- As indicated on a medical history form they complete, any individual who is currently being treated for or diagnosed with any cardiac, respiratory, endocrine, psychiatric, musculoskeletal, renal, hepatic, neuromuscular or metabolic disease or disorder.
- Additional exclusion criteria include: participants with a fasting capillary blood glucose level > 100 mg/dL.
- Current smokers (including vaping) or have quit within the past six months.
- Any over-the-counter or prescription drugs and/or dietary supplements that are known or are purported to impact glycemia and insulinemia.
- Currently or have been following with the past 30 days a ketogenic or very-low carbohydrate diet.
- Participants who are determined to not be weight stable defined as measured body mass deviating by 2% or more.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Maltodextrin
|
For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast.
Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured.
After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion.
After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water.
The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
|
|
Active Comparator: Berberine
500 mg of Berberine
|
For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast.
Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured.
After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion.
After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water.
The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
|
|
Active Comparator: Dihydroberberine 200
200 mg of Dihydroberberine
|
For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast.
Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured.
After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion.
After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water.
The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
|
|
Active Comparator: Dihydroberberine 100
100 mg of Dihydroberberine
|
For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast.
Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured.
After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion.
After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water.
The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Berberine
Time Frame: 30 days
|
Changes in plasma berberine levels after supplementing 500 mg of berberine
|
30 days
|
|
Dihydroberberine 200
Time Frame: 30 days
|
Changes in plasma berberine levels after supplementing 200 mg of dihyrdoberberine
|
30 days
|
|
Dihydroberberine 100
Time Frame: 30 days
|
Changes in plasma berberine levels after supplementing 100 mg of dihyrdoberberine
|
30 days
|
|
Glucose
Time Frame: 30 days
|
Changes in plasma glucose levels after supplementing either berberine or dihyrdoberberine
|
30 days
|
|
Insulin
Time Frame: 30 days
|
Changes in insulin levels after supplementing either berberine or dihyrdoberberine
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Chad Kerksick, PhD, Lindenwood University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB-20-173
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.